Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.
Also called NCT02053909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 250 participants
- Registry
-
NCT02053909
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02053909. Randomized; quadruple masking; primary purpose prevention. Start 2014-09 (registry gives no type); primary completion 2020-08 (actual). Results posted on 2022-09-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
- Acronym
- TARGET
- Condition
- Saphenous Vein Graft Disease
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Ticagrelor
- Lead sponsor
- Boca Raton Regional Hospital
- Collaborator
- AstraZeneca
- Collaborator
- Ottawa Heart Institute Research Corporation
Record details
- Record id
cardio:ct-nct02053909- Content hash
a1580ae9fade3d2ffd54959f1c810863ca505e5c663e074ad79aeb5a82af2c2f